A detailed history of Hikari Power LTD transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Hikari Power LTD holds 49,959 shares of CRVS stock, worth $239,803. This represents 0.02% of its overall portfolio holdings.

Number of Shares
49,959
Previous 49,959 -0.0%
Holding current value
$239,803
Previous $91,000 190.11%
% of portfolio
0.02%
Previous 0.01%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

Apr 13, 2022

BUY
$1.46 - $2.48 $43,800 - $74,400
30,000 Added 150.31%
49,959 $82,000
Q3 2020

Oct 08, 2020

SELL
$2.6 - $5.37 $106,600 - $220,170
-41,000 Reduced 67.26%
19,959 $80,000
Q1 2020

Apr 23, 2020

SELL
$1.74 - $5.98 $33,131 - $113,865
-19,041 Reduced 23.8%
60,959 $129,000
Q4 2019

Feb 04, 2020

SELL
$2.56 - $5.44 $128,000 - $272,000
-50,000 Reduced 38.46%
80,000 $435,000
Q4 2018

Jan 29, 2019

BUY
$3.29 - $8.94 $322,123 - $875,315
97,910 Added 305.11%
130,000 $477,000
Q3 2018

Oct 31, 2018

BUY
$8.58 - $11.4 $275,332 - $365,826
32,090 New
32,090 $275,000

Others Institutions Holding CRVS

About Corvus Pharmaceuticals, Inc.


  • Ticker CRVS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,553,500
  • Market Cap $223M
  • Description
  • Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...
More about CRVS
Track This Portfolio

Track Hikari Power LTD Portfolio

Follow Hikari Power LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hikari Power LTD, based on Form 13F filings with the SEC.

News

Stay updated on Hikari Power LTD with notifications on news.